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To my patients
  
ABSTRACT 
 
In the last decades, new treatments for bipolar disorder (BD) have emerged, prompting 
a decrease in the use of lithium – the former “gold standard” for relapse prevention, and 
increasing the possibilities for individualized treatment. The aims of this thesis were to: 
1) explore the use of relapse prevention in the early phases of bipolar illness, 2) add to 
the current knowledge concerning the comparative effectiveness of various 
pharmacological maintenance treatments, including combination therapies, and 3) 
explore the use of benzodiazepines and non-benzodiazepine hypnotics (so called Z-
drugs) in BD. All four studies were population based cohort studies, using data from 
Swedish national registers. 
 
In Study I, 31 770 individuals with newly diagnosed BD were followed for one year with 
regard to initiation of relapse prevention. Three months after diagnosis, 72% had 
initiated such treatment. Patients diagnosed with BD during a long hospitalization were 
most likely to initiate treatment, followed by patients who had used lithium, 
anticonvulsants or antipsychotics prior to diagnosis. Our findings indicate that efforts to 
reduce treatment delay should especially target patients who are naïve to mood-
stabilizers and antipsychotics or diagnosed with BD during a brief hospitalization. 
 
In Study II, we followed patients for one year after a hospitalization for a manic episode. 
The study included follow-up data from 6 502 hospitalizations. We classified patients by 
various prophylactic drug regimens, based on prescription fills during the first four 
weeks after hospital discharge, and assessed the one-year rehospitalization risk 
associated with each regimen. Combination therapy with olanzapine and valproate or 
lithium was associated with the lowest rehospitalization risk. 
 
Study III had a design similar to Study II, but investigated the risk of treatment failure 
with various treatment alternatives. Treatment failure was defined as treatment 
switch/discontinuation or rehospitalization during ongoing treatment. We found that 
treatment failure was less common in patients on combination therapy, and that 
combination therapies including lithium, valproate and quetiapine or olanzapine were 
associated with the lowest risks of treatment failure. 
 
In Study IV, we included 21 883 BD patients with no history of benzodiazepine/Z-drug 
use in the past year and followed them for one year with regard to benzodiazepine/Z-
drug initiation and long-term use (continuous use for ≥6 months). In total, 6 307 
patients (29%) initiated benzodiazepine/Z-drug treatment, of whom more than one in 
five became long-term users. Most notably, patients who initiated treatment with 
clonazepam or alprazolam had greatly increased odds for long-term use. In addition, 
long-term use was common among patients who used two or more benzodiazepines 
and/or Z-drugs. 
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1 INTRODUCTION 
 
Although the first writings capturing bipolar disorder date back to the ancient Egyptians,1 
it took until the early 20th century before the nature of the illness was described in 
greater detail. In 1921, German psychiatrist Emil Kraepelin distinguished “manic-
depressive insanity” from the previously unitary concept of psychosis,2 enabling 
subsequent studies of its specific features and treatments. 
 
1.1 Bipolar disorder 
Bipolar disorder is characterized by recurrent episodes of mania and depression, 
typically with onset during adolescence or early adulthood.3 Mania distinguishes 
bipolarity from unipolar depressive illness and involves elevated or irritable mood, 
increased activity, inflated self-esteem, pressure of speech and decreased need for sleep.4 
Nevertheless, the clinical presentation is usually dominated by depression, both in terms 
of number of episodes throughout life, and of days spent symptomatic.5-7 
 
The DSM-5 recognizes two distinct subtypes of bipolar disorder: type I and type II.4 
Bipolar disorder type I encompasses a more severe form of manic episodes with 
significant loss of function and/or psychotic symptoms, whereas individuals with bipolar 
disorder type II experience a less severe form referred to as hypomania. The lifetime 
prevalence of bipolar disorder type I is about 1% in both men and women.8,9 The lifetime 
prevalence for bipolar disorder type II is slightly higher, with a small female 
overrepresentation.3 Yet another 2% of the population is estimated to suffer from 
subthreshold forms of bipolar illness, resulting in a lifetime prevalence of so called 
bipolar spectrum disorders of over 4%.3  
 
Epidemiological studies have found that the prevalence of bipolar disorder has increased 
in the last decades,10-12 possibly reflecting a diagnostic shift from schizophrenia to other 
psychiatric disorders.11,12 Despite this increased recognition of bipolar symptomatology, 
there is still a considerable lag time between the onset of bipolar illness and bipolar 
disorder diagnosis,13,14 which may lead to delayed initiation of adequate treatment.13-15 
 
1.2 Morbidity 
Until recently, the view of bipolar disorder has been heavily influenced by Kraepelin’s 
description of manic depressive illness, with a return to normal mood – euthymia – and 
unimpaired functioning between episodes.2 However, recent evidence shows that a 
majority of patients suffer from significant inter-episodic morbidity, experiencing 
subsyndromal manic and depressive symptoms,7,16,17 as illustrated in Figure 1. The 
characteristic relapses of threshold mania and/or depression affect over 90% of 
patients.18 Observational studies estimate the two-year syndromic relapse risk to around 
50%,6,19 with five-year relapse risks ranging from 70% to 90%.19,20 In addition to affective 
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morbidity, up to 75% of bipolar disorder patients suffer from at least one comorbid 
psychiatric condition.21 Anxiety disorders and substance use disorders are the most 
common comorbidities, affecting between 25% and 50% of patients at some point in 
life.22,23 
 
 
 
 
Figure 1. The typical variable course of bipolar disorder. 
 
 
1.3 Social and economic aspects 
Bipolar illness has significant social and economic impacts on personal life. It affects 
interpersonal relationships, as illustrated by a 50% lower marriage rate among patients 
compared to the general Swedish population.24 Starting out with an educational level 
similar to that of their peers,25 future employment rates were found to be up to 60% 
lower among individuals with bipolar disorder in a systematic review of 25 studies from  
Europe, USA and China.26 Many patients report that their illness forces them to change 
their job to a less demanding position, resulting in a downward drift of occupational 
status.26  
 
Further, bipolar disorder also has economic implications on society. The annual cost per 
bipolar disorder patient in Sweden was estimated to 28 011 Euro in 2008, of which 
indirect costs due to sick leave and early retirement represented 75%.24 The total cost 
was six times higher during threshold mood-episodes and increased drastically during 
hospitalizations (55 500 vs 22 200 Euro).24 Between 50% and 60% of all direct costs 
could be attributed to hospitalization.24,27  
 
1.4 Mortality 
Although a majority of patients with bipolar disorder die from somatic disease, bipolar 
disorder is associated with the highest suicide risk of all psychiatric conditions.28 The risk 
of suicide is significantly increased throughout the lives of bipolar disorder patients, 
though most pronounced in younger ages and in the first years after diagnosis, when the 
risk is seven times higher compared to the general population.29 Between 25% and 50% 
of all patients attempt suicide at some point,30,31 usually during a depressive or mixed 
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episode.32 In Sweden, suicide accounts for between 5% and 10% of deaths in individuals 
with bipolar disorder, compared to circa 1% in the general population.33  
 
1.5 Bipolar disorder treatment – an historical overview 
After Kraepelin’s characterization of bipolarity in the early 20th century, a variety of 
treatments targeted against manic depressive illness were launched. Psychodynamic 
theories for psychotherapy in depression were developed based on Freud’s 
psychoanalytical doctrine,34 followed by surgical procedures including prefrontal 
lobotomy, introduced in the 1930’s.34,35 Shortly thereafter, electroconvulsive therapy was 
developed,36 and has remained a viable treatment option for drug resistant bipolar 
depression, mania, mixed state and catatonia.37 
 
In the 1950’s, the treatment of psychiatric illness took a leap forward due to the 
development of effective psychotropic drugs,34 including first generation 
antidepressants,34 antipsychotics,34 and benzodiazepine anxiolytics.38 The Australian 
physician John Cade showed that lithium  a natural salt used to treat gout   could reduce 
“psychotic excitement” related to mania,39 paving the way for a subsequent clinical trial 
by Danish psychiatrist Mogens Schou. Schou and colleagues published their results in 
1954, concluding that lithium could be used for relapse prevention in bipolar disorder.40 
This caused a therapeutic shift from only focusing on the alleviation of acute manic or 
depressive symptoms to preventing new affective episodes from developing. 
 
1.6 Modern treatment approaches 
Maintenance treatment with lithium or anticonvulsants (jointly referred to as “mood-
stabilizers”) or atypical antipsychotics is currently the cornerstone of bipolar disorder 
management, for which the ultimate goals are relapse prevention, reduction of 
subthreshold symptoms, and enhanced social and occupational functioning.41 In addition, 
acute pharmacological treatment is used during depressive and 
manic/hypomanic/mixed relapses to achieve faster symptomatic recovery.41 These 
complementary pharmacological approaches are illustrated in Figure 2. 
 
Table 1 shows all mood-stabilizers and antipsychotics with regulatory approval for the 
treatment of bipolar disorder in Sweden, and their specific indications.42 In addition to 
the listed drugs, antidepressants are widely used to tackle the depressive 
symptomatology in bipolar disorder.43 There has been a long-standing debate about the 
potential pros and cons with such treatment, including mood-destabilization and manic 
switch.44 However, new data suggest that the risk for manic switch is low, if the 
antidepressant is used in combination with a mood-stabilizer.45 
 
Short-term add-on treatment with benzodiazepines or non-benzodiazepine hypnotics 
may also be necessary when an acute stressor is imminent or present, that may trigger 
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relapse. Such drugs are further used to tackle early symptoms of relapse (especially 
insomnia) and prominent anxiety.46 
 
Figure 2. Pharmacological approaches throughout the course of bipolar disorder 
(modified from Frank et al. 199147). 
 
 
 
 
 
 
Table 1. Mood-stabilizers and antipsychotics with regulatory approval for treatment 
of bipolar disorder in Sweden 
 Indication: 
 Acute mania Acute depression Relapse prevention 
Lithium x  x 
Anticonvulsants:    
Lamotrigine   x 
Valproate x  x 
Antipsychotics:    
Aripiprazole x  x 
Chlorprothixene x   
Haloperidol x   
Levomepromazine x   
Olanzapine x  x 
Paliperidone x   
Perphenazine x   
Quetiapine x x x 
Risperidone x   
Ziprasidone x   
Zuclopenthixol x   
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1.7 Maintenance treatment 
As illustrated in Table 1, only six out of the 14 drugs approved for bipolar disorder 
treatment in Sweden are indicated for relapse prevention: lithium, lamotrigine, 
valproate, aripiprazole, olanzapine and quetiapine. Just as for acute treatment, these 
drugs differ in terms of their relative antimanic versus antidepressive preventive efficacy 
(so called polarity index).48 In brief, lithium and quetiapine have been shown to prevent 
both manic and depressive episodes, whereas lamotrigine mainly prevents depressive 
episodes and olanzapine and aripiprazole mainly prevent manic episodes.48 Data on the 
polarity index of valproate have so far been inconclusive,48,49 although its prophylactic 
efficacy is well established.49 
 
Despite the growing pharmacopoeia of mood-stabilizers and antipsychotics, lithium 
remains the first line maintenance treatment recommended by the Swedish National 
Board of Health and Welfare.50 The British Association for Psychopharmacology (BAP), 
the World Federation of Societies of Biological Psychiatry (WFSBP), and the National 
Institute for Health and Care Excellence (NICE) have the same approach in their 
treatment guidelines,46,51,52 whereas the Canadian Network for Mood and Anxiety 
Treatments (CANMAT) and the International College of Neuro-Psychopharmacology 
(CINP) have shifted towards recommending monotherapy with lithium or specific 
anticonvulsants or antipsychotics.53,54 So far, CANMAT is the only large-scale guideline to 
also recommend combination treatments as first-line.53  
 
Comparative effectiveness of maintenance treatments 
Treatment recommendations are so far primarily based on findings from RCTs. To date, 
the majority of clinical trials of maintenance treatment in bipolar disorder have evaluated 
the efficacy of one atypical antipsychotic (in monotherapy or as add-on), compared to 
one or two mood-stabilizers and/or placebo. Furthermore, the real-world effectiveness 
of maintenance treatment has been assessed through observational studies, which have 
typically included a greater number of treatment alternatives. However, these 
observational studies have also been restricted to only studying one atypical 
antipsychotic at a time, and few, if any, combination therapies.55-59 As studies from 
around the world show a rapid increase in the use of antipsychotics and combination 
therapies,60-62 the lack of comparative data on these treatments has become 
increasingly problematic. 
 
Discrepancies between RCT findings and observational data add to the complexity when 
choosing between different treatment options. Whereas RCTs have typically shown an 
equal or superior effectiveness of antipsychotics compared to lithium or valproate,49,63 
the majority of observational studies have found a superior effectiveness of lithium over 
other drugs.57-59,64,65 How can this be? For one, translating findings from RCTs to clinical 
reality is challenging. For practical and scientific reasons, RCTs have narrow inclusion 
and exclusion criteria, limiting their generalizability.66,67 Furthermore, the vast majority 
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of maintenance treatment RCTs have a so called “enrichment design”, meaning that they 
only include patients who have responded well to the new drug of study during an acute 
affective episode.66,67 Patients are thereafter randomized to either continuing with the 
new drug or using an older treatment alternative, which makes it difficult to demonstrate 
the effect of old drugs. Likewise, patients who are satisfied with their current treatment 
are likely less prone to participate in a randomized trial evaluating the efficacy of a new 
drug, also favoring new treatment alternatives. 
 
Observational studies on their part may contain unrecognized confounding factors that 
distort results, as patients are not randomized to treatments.68 For this reason, 
randomized controlled trials top the hierarchy of study designs traditionally used in 
evidence based medicine (after systematic reviews and other types of evidence 
synthesis), followed by cohort and case-control studies (Figure 3).69,70 However, two 
comprehensive reviews comparing the estimated efficacy of drugs in RCTs versus 
observational studies, each including over 100 studies, show that well-designed 
observational studies (with either a cohort or case–control design) do not systematically 
over- or underestimate the magnitude of the effects of treatment as compared with RCTs 
on the same topic.71,72 These insights, and the discrepancies between RCT findings and 
real-world clinical experience, have led to a call for a shift from the pyramidal shaped 
hierarchy of study designs to a broader multi-domain perspective when psychiatric 
treatment guidelines are created (Figure 3).70 
 
Early versus late initiation of maintenance treatment 
Despite the increasing recognition of bipolar disorder in clinical settings, there is often a 
considerable delay from illness onset to diagnosis and to initiation of prophylactic 
treatment.13,15,25,73,74 Delayed treatment initiation has been associated with poorer social 
adjustment, more frequent hospitalizations, and increased suicidal behavior.15,74 
Furthermore, the higher employment rates in early versus late bipolar disorder 26 
suggest that early intervention may be beneficial with regard to maintaining the capacity 
to work. 
 
In line with these findings, consistent evidence show that early pharmacological 
intervention is more effective than intervention later during the illness course, with 
regard to response rates, relapse rates, time to recurrence, symptomatic recovery, and 
remission.75-78 However, most treatment guidelines do not specify when long-term 
prophylactic treatment should be initiated.79 The guidelines on bipolar disorder 
management published by the Swedish National Board of Health and Welfare in 2010 
stated that treatment should be initiated “urgently”.50 
 
In addition to delayed initiation of treatment due to diagnostic lag time and for other 
reasons, treatment non-adherence greatly contributes to an impaired prognosis.80 
Previous observational studies have estimated that 20%70% of patients are non-
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adherent to medication in the early phases of prophylactic treatment.81-88 Among the 
factors most consistently associated with non-adherence to maintenance treatment are 
substance abuse 80,81,86,88,89 and comorbid personality disorder.90,91 
 
 
  
  
Figure 3, from Salvador-Carulla et al. 2017,70 illustrating the shift from a pyramid shaped 
hierarchy of study designs to a broader multi-domain perspective: the Greek temple model 
of scientific knowledge. 
 
 
1.8 Benzodiazepines and Z-drugs 
Benzodiazepines and sleep inducing hypnotics (so called “Z-drugs”) are the third most 
used group of psychotropics in bipolar disorder in Sweden, after antidepressants and 
atypical antipsychotics.60 These substances are effective and well tolerated in the short-
term management of anxiety and insomnia,92,93 through binding to the γ-aminobutyric 
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acid (GABAA) ionotropic receptor and facilitating its inhibiting actions on neuronal 
activity.94,95 The anxiolytic and hypnotic effects of benzodiazepines and Z-drugs can be 
used to reduce the risk of relapse in patients experiencing acute stress. They are further 
prescribed to patients with early symptoms of relapse in order to prevent development 
of full-scale manic or depressive episodes, and to treat anxiety, agitation and/or insomnia 
during manic, mixed or depressed episodes.46 Lastly, comorbid anxiety disorders96 and 
inter-episodic sleep disturbances97 may require benzodiazepine treatment. 
 
Tolerance, dependence and abuse 
Although benzodiazepines are demonstrated to be safe for short-term use,98 the risks of 
tolerance, dependence and abuse during long-term treatment have been increasingly 
recognized.99 Tolerance means that chronically treated patients become less sensitive to 
some treatment effects over time, specifically to the anticonvulsant, sedative, hypnotic, 
and myorelaxant effects of benzodiazepines.100 Dependence is characterized by a 
combination of tolerance, withdrawal symptoms when drug intake is stopped, and dose 
escalation,101 and develops in approximately half of all patients who use benzodiazepines 
for longer than one month.102 Dependence and an activation of dopaminergic neurons in 
the brain’s “addiction network” may further result in benzodiazepine/Z-drug abuse.103  
 
Other risks associated with long-term benzodiazepine use 
In addition to tolerance, dependence, and abuse, continuous use of benzodiazepines has 
been associated with impaired cognitive functioning104,105 and increased risk of 
accidental falls106,107. Further, studies suggest a dose-response relationship between 
benzodiazepines and the development of Alzheimer’s disease108 and all-cause 
mortality109. Bipolar disorder patients with a regular use of benzodiazepines show higher 
levels of treatment resistance to mood-stabilizers110 and have a greater risk for both 
manic and depressive relapses, independently from the effects of comorbid anxiety and 
insomnia.60 Benzodiazepines also seem to have direct depressogenic effects,111,112 which 
may be particularly harmful to individuals with bipolar disorder. 
 
Epidemiology of long-term benzodiazepine use 
Due to the potentially harmful effects described above, benzodiazepine use has decreased 
in the past decades,60,92,113 and clinical guidelines consistently recommend that treatment 
with benzodiazepines/Z-drugs should be kept as short as possible, with a maximum of 
four weeks.114-116 However, observational studies have found that 15%35% of 
benzodiazepine users continue with their treatment for substantially longer periods of 
time.117-120 Elderly patients seem to have the highest rates of long-term use.119,120 Other 
identified risk factors include male gender, short-acting or mixed type agents, and high 
initial doses.117,118
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2 OBJECTIVES 
 
The overall objectives of this thesis were to explore the use of maintenance treatment 
and benzodiazepines in bipolar disorder, to assess if and how prescription patterns 
diverge from treatment guidelines, and to compare outcomes across patients using 
various pharmacological maintenance treatments, including combination therapies. 
 
Specific objectives for each of the four studies were: 
I.  To assess the use of, and predictors for, maintenance treatment in newly 
diagnosed bipolar disorder patients.  
II.  To study the rehospitalization risk in patients discharged from a hospitalization 
for mania, and to compare rehospitalization risks across the entire span of 
treatment options approved for prophylactic use after a manic episode, including 
combination therapies. 
III.  To compare risks of treatment failure after a manic episode across the entire 
span of treatment options approved for prophylactic use after a manic episode, 
including combination therapies. 
IV.  To study the incidence of, and predictors for, long-term use of benzodiazepines 
and Z-drugs in bipolar disorder. 
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3 MATERIALS AND METHODS 
 
3.1 Setting 
The four studies included in this thesis were performed in Sweden. Sweden has a long 
tradition of recording the major life events of all residents, dating back to the 17th century. 
The collection of sociodemographic data was originally a task for the Swedish Lutheran 
church, but was gradually taken over by state agencies during the 20th century. In the 
1960’s, the Swedish National Board of Health and Welfare started to collect healthcare 
data for quality control, which became the starting point for the longitudinal population-
based health registers on which our studies are based. As reporting to these registers is 
mandatory for all healthcare providers, coverage is high. Further, healthcare is public and 
equally accessible to all Swedish residents, preventing selection processes due to 
insurance coverage. The unique personal identification number assigned to all Swedish 
residents at birth or immigration enabled us to link information across registers, merging 
socioeconomic, demographic and healthcare data.  
 
3.2 Data sources 
The Swedish National Patient Register (NPR) 
The NPR is kept by the Swedish National Board of Health and Welfare. It covers all 
inpatient care in Sweden from 1987 and onwards. Further, psychiatric outpatient care 
provided by public or private caregivers has been fully covered since 2001. Registered 
information include hospital admission and discharge dates, dates for outpatient visits, 
and diagnoses assigned by the treating physician coded according to the International 
Classification of Diseases, 9th revision (ICD-9), since 1987, and 10th revision (ICD-10), 
since 1997.121 External validations show that 99% of all somatic and psychiatric hospital 
discharge diagnoses are recorded in the NPR.122 The validity of bipolar disorder 
diagnoses recorded in psychiatric outpatient care has never been assessed, however, the 
validity of a bipolar disorder diagnosis recorded in psychiatric inpatient care is high, with 
a positive predictive value of 0.81.123 
 
The Prescribed Drug Register (PDR) 
The PDR contains information on all drugs dispensed in Swedish pharmacies since July 
2005.124 Available data include the date of dispensing, amount, substance name and 
World Health Organization’s Anatomical Therapeutic Chemical Classification (ATC) code. 
Eighty-four percent of the total drug utilization in Sweden is covered in the PDR, with the 
remaining 16% representing over-the-counter drugs.125 As all drugs studied in this thesis 
were prescription drugs, we expect missing data on drug exposure to be minimal.  
 
The Cause of Death Register (CDR) 
The CDR was established in 1961, and contains information on the date and cause of 
death of all Swedish residents who have passed away since. From 2011 and onwards, it 
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also includes information on Swedish residents who have passed away abroad.126 The 
register is complete with regard to capturing all deaths along with the date.126 However, 
the validity of the registered causes of death (recorded through ICD diagnosis codes) 
vary, with the highest validity seen in patients who die in hospitals.127 For this thesis, 
dates of death were used for exclusion or censoring purposes, whereas causes of death 
were not considered. 
 
The Total Population Register (TPR)  
The TPR is maintained by the government agency Statistics Sweden and holds 
information on major life events of all residents, including birth, death, marital status, and 
migration within Sweden, and to and from other countries. Updated information is 
transmitted daily from the Tax Agency.128 A recent validation study found that virtually 
100% of births and deaths, 95% of immigrations, and 91% of emigrations are reported 
to the TPR within 30 days.128 
 
The Longitudinal Integration Database for Health Insurance and Labor Market 
Studies (LISA) 
The LISA database is maintained by Statistics Sweden in collaboration with the Social 
Insurance Agency. It integrates data from the labor market, educational and social 
sectors, and is updated annually. Registered information include the disposable income 
and highest level of education of all Swedish residents.129 
 
3.3 Cohort study design 
The studies comprising this thesis were all nationwide population based cohort studies. 
A cohort study is designed to investigate the association between one or several 
exposures and outcomes. At baseline, the included subjects have to be free from, but 
susceptible to, the outcome of interest. Study participants are grouped based on exposure 
status, and followed with regard to study outcomes. Exposures can either be assessed 
just once or be time dependent, allowing for patients to change exposure status during 
follow-up. Likewise, outcome events can be measured either at the end of the study 
period, without considering when during follow up the outcome event occurred, or in a 
time dependent fashion, using “time to outcome event” as primary outcome. Each study 
subject contributes with person-time during the period he or she is part of the study and 
remains susceptible to the outcome. Typically, the accumulated person-time from all 
study subjects is summarized in person-years. Potential confounders associated with the 
study exposure and outcome can be measured in the same fashion as exposures, and 
accounted for in the analyses. Cohort studies are especially useful if the investigated 
exposure(s) is rare and the outcome(s) is expected to be relatively common among study 
subjects. The basic cohort study design is illustrated in Figure 4.  An overview of the four 
studies in this thesis is presented in Table 2. 
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Figure 4. Illustration of the basic cohort study design, in which the occurrence of outcome 
events (illustrated with red X’s) is compared between exposure groups at the end of the 
study period. 
 
 
Table 2. Overview of studies included in the thesis 
 Study I Study II Study III Study IV 
Design Cohort Cohort Cohort Cohort 
Population Swedish residents 
aged 1875 years 
with a first time 
BD diagnosis 
Swedish residents 
aged 1875 years 
hospitalized for a 
manic episode 
Swedish residents 
aged 1875 years 
hospitalized for a 
manic episode 
Swedish residents 
aged 1875 years 
with a BD or 
mania diagnosis 
and no ongoing 
benzodiazepine/Z-
drug use  
Number 31 770 6 502 index 
hospitalizations 
representing  
4 250 patients 
5 713 index 
hospitalizations 
representing  
3 772 patients 
21 883 
Study period July 2006  
December 2012 
July 2006  
December 2014 
July 2006  
December 2014 
July 2006  
December 2014 
Data sources NPR 
PDR 
CDR 
NPR 
PDR 
CDR 
TPR 
LISA-register 
NPR 
PDR 
CDR 
TPR 
LISA-register 
NPR 
PDR 
CDR 
TPR 
LISA-register 
Exposures Age, sex, BD 
characteristics, 
psychiatric 
history and 
concurrent 
medication 
Pharmacotherapy 
used for relapse 
prevention during 
the first four 
weeks after 
discharge 
(monotherapies & 
combinations) 
Active treatment 
periods with 
maintenance 
treatment after 
discharge 
(monotherapies &  
combinations) 
Sociodemographic 
characteristics, BD 
characteristics, 
physical health 
characteristics and 
concurrent 
medication 
Outcomes Initiation of 
prophylactic 
treatment  within 
three months and 
one year after BD 
diagnosis 
Rehospitalization 
within one year 
Treatment failure 
within one year 
Initiation of 
benzodiazepine/Z-
drug treatment 
within one year 
and subsequent 
long-term use 
BD – bipolar disorder 
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3.4 Study I  
Study population 
All patients aged 18 to 75 years with a first time bipolar disorder diagnosis in specialist 
psychiatric care between July 1, 2006 and December 31, 2012 were identified in the NPR 
and included in the study (N=31 978). A first time bipolar disorder diagnosis was defined 
as having no previously registered bipolar disorder diagnosis in the NPR since 1987. 
Patients with a diagnosis of schizophrenia or schizoaffective disorder registered on the 
same day as the bipolar disorder diagnosis were excluded due to the risk of 
misclassification, resulting in a final study population of 31 770 individuals. 
 
Exposures 
The following factors were studied as potential predictors for initiation of prophylactic 
treatment within three months after diagnosis: age, sex, affective state at diagnosis, 
presence of psychotic symptoms at diagnosis, psychiatric care in the past five years, self-
harm in the past five years, duration of the index hospitalization, use of any psychotropic 
medication in the past year and comorbid substance abuse. 
 
Outcomes 
The primary outcome was time to filling a prescription of a mood-stabilizer or an 
antipsychotic within one year after diagnosis. The secondary outcome was time to filling 
a prescription of a mood-stabilizer or an antipsychotic within three months after 
diagnosis. Mood-stabilizers were defined as lithium, carbamazepine, lamotrigine, and 
valproate. 
 
3.5 Study II 
Study population 
All individuals aged 18 to 75 years who were hospitalized for a manic episode at any point 
between July 1, 2006 and December 31, 2014 were identified in the NPR and included in 
the study upon hospital discharge (N=5 234). Patients who were hospitalized for mania 
multiple times during the study period were included as such (i.e. after each 
hospitalization), rendering a total of 8 881 index hospitalizations. Patients with a 
previous diagnosis of schizophrenia, schizoaffective disorder, or dementia were 
excluded, as were patients who were not Swedish residents or who emigrated from 
Sweden, died, or were rehospitalized within four weeks after hospital discharge.  The 
final study included follow-up data from 6 502 index hospitalizations, representing 4 250 
patients. 
 
Exposures 
Patients were allocated to different exposure groups based on what type of 
pharmacological relapse prevention they used during the first four weeks after hospital 
discharge. Lithium, valproate, olanzapine, quetiapine and aripiprazole were the only 
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drugs considered as relapse prevention, based on their regulatory approval for 
prophylactic use after a manic episode. Patients who filled one or more prescriptions of 
the same drug were classified as using monotherapy, whereas patients who filled 
prescriptions of two or more different drugs were considered to use combination 
therapy. 
 
Outcome  
The primary outcome was time to rehospitalization within one year after discharge. 
Follow-up started four weeks after discharge. 
 
Potential confounders 
The results were adjusted for potential confounders, including prescription fills of other 
psychotropic drugs, proxy variables for the severity of the manic index episode, the 
psychiatric history of the patient and socioeconomic and demographic data. 
 
3.6 Study III 
Study population 
Swedish residents aged 18 to 75 years who were hospitalized for a manic episode at 
any point between July 1, 2006 and December 3, 2014 were identified in the NPR and 
included in the study upon hospital admission. Individuals with several hospitalizations 
for mania during the study period were included upon each such hospitalization. 
Patients were not allowed to have a previous diagnosis of schizophrenia, schizoaffective 
disorder, or dementia. This rendered a total of 4 628 included patients and 7 635 
included index hospitalizations. Hospitalizations ending later December 3, 2014 were 
excluded, as were patients who: 1) had not been Swedish residents for a full year prior 
to hospital admission, 2) died during the index hospitalization, 3) did not start 
maintenance treatment within four weeks after hospital discharge, 4) were readmitted 
before starting maintenance treatment, or 5) fulfilled criteria for medication switch 
during the index hospitalization. The final cohort included 3 772 patients and 5 713 
index hospitalizations. 
 
Exposures 
Patients were allocated to different exposure groups based on what type of maintenance 
treatment they used after hospital discharge. Whereas Study II had more of an 
observational “intention-to-treat” design in which only treatment initiation was 
considered, active treatment periods of lithium, valproate, olanzapine, quetiapine, and 
aripiprazole, alone or in combinations, were recorded in Study III. An active treatment 
period was defined as starting on the day of a prescription fill of any of the studied 
drugs, or on the day of hospital discharge if the patient filled one or several 
prescriptions during the index hospitalization. Patients who filled prescriptions of more 
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than one drug in a time period of less than two weeks were considered to use 
combination therapy. 
 
Outcomes 
Time to treatment failure was our primary outcome. We defined treatment failure as: 
1) stopping of medication, 2) switch of medication, or 3) readmission to inpatient 
psychiatric care during an active treatment period. Stopping of medication was defined 
as not having access to medication for a period of ≥28 days, based on our calculations. 
Patients who started off with a combination therapy and subsequently stopped one 
drug while continuing with the other/others were not considered to have stopped 
medication. Medication switch was defined as filling a prescription of another 
psychotropic drug (mood-stabilizer, antipsychotic, antidepressant, or anxiolytic) 
during an active treatment period or within 28 days after an active treatment period. 
Finally, readmission to psychiatric inpatient care was considered a treatment failure, 
including admissions to somatic inpatient care due to suicide attempts. 
 
Follow-up started on day 14 of the first active treatment period and ended after 365 
days or upon the earliest of any of the following events: treatment failure, emigration, 
death, or the end of the study period; December 31, 2014. 
 
Potential confounders 
As in Study II, information on potential confounders, including prescription fills of other 
psychotropic drugs, proxy variables for the severity of the manic index episode, the 
psychiatric history of the patient and socioeconomic and demographic data were 
included in the analyses. 
 
3.7 Study IV 
Study population 
All patients aged 1875 years with a registered diagnosis of bipolar disorder or mania 
in specialist care between July 1, 2006 and December 31, 2012 were identified through 
the NPR (N=46 535). Patients with no recorded use of any benzodiazepine or Z-drug in 
the preceding year (N=23 282) were included in the study on the day of their first 
registered bipolar disorder or mania diagnosis during the study period (defined as the 
bipolar disorder index date). Patients who had not been Swedish residents for a full 
year or had a previous diagnosis of schizophrenia, schizoaffective disorder, or 
dementia, were excluded. In total, 21 883 patients were included in the bipolar disorder 
cohort. Patients in the bipolar disorder cohort who initiated benzodiazepine or Z-drug 
treatment within one year (N=6 307) were subsequently transferred to the 
benzodiazepine initiator cohort on the day of their first benzodiazepine/Z-drug 
prescription fill (defined as the index dispensing date). 
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Exposures 
Sociodemographic characteristics, bipolar disorder related characteristics, physical 
health characteristics and concomitant psychotropic medication were investigated as 
potential predictors for benzodiazepine or Z-drug initiation and subsequent long-term 
use. In addition, the association between factors related to the first filled 
benzodiazepine/Z-drug prescription and subsequent long-term use was explored. 
 
Outcomes 
The primary outcome in the first part of the study was benzodiazepine or Z-drug 
initiation within one year after study inclusion, defined as at least one prescription fill 
of diazepam, oxazepam, lorazepam, alprazolam, clonazepam, nitrazepam, flunitra-
zepam, triazolam, zopiclone, zolpidem, or zaleplon. Patients were followed for up to one 
year from the bipolar disorder index date. The primary outcome in the second part of 
the study was long-term benzodiazepine/Z-drug use, defined as continuous use of one 
or several benzodiazepines and/or Z-drugs for more than 180 days, from the index 
dispensing date. 
 
3.8 Statistical analyses 
The Kaplan-Meier estimator (Study I-III)  
The Kaplan-Meier estimator is a non-parametric statistical tool that estimates the 
survival function – the probability to stay alive over time,130 or, as in our studies, the 
probability not to acquire the studied outcome. It takes into account all observed 
outcome events and can be used with censored data, under the premise that the reason 
for censoring is independent of the outcome (non-informative censoring).  
 
We used the Kaplan-Meier estimator to study the proportion of patients in each exposure 
group without rehospitalization or treatment failure in Study II and III. The complement 
of the survival curve generated by the Kaplan-Meier estimator – the cumulative incidence 
curve – was further used to illustrate rates of prescription fills of prophylactic drugs after 
a first time bipolar disorder diagnosis in Study I. 
 
Cox proportional hazard regression (Study I-III) 
The Cox proportional hazard regression model is a statistical survival model that 
estimates the risk of acquiring the outcome, referred to as the hazard function. It 
estimates the ratio between two hazard rates, but cannot estimate each individual hazard 
rate, which in theory describes the outcome rate for an item at a given time point.131 
Unlike the Kaplan-Meier estimator, the Cox proportional hazard regression model allows 
the estimation of the hazard ratio of an exposure while simultaneously accounting for the 
effects of other variables. This so called multivariable regression is used to adjust for 
confounding factors. The Cox proportional hazard regression model is based on the key 
assumption of proportional hazards, meaning that the survival curves of two exposures 
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must have hazard functions that are proportional over time (i.e. that the hazard ratio is 
constant). For the estimated ratio and confidence interval to be accurate, the variance in 
the data also has to be constant. 
 
We used the Cox proportional hazard regression model to estimate hazard ratios for the 
initiation of pharmacoprophylaxis in Study I and for rehospitalization and treatment 
failure in Study II and III, assuming that the investigated hazards were proportional. 
 
The sandwich covariance estimator (Study II-III)   
For data that consists of small groups of correlated observations, the standard 
covariance estimate of the Cox model may be invalid due to non-constant variance in 
the sample because of dependence among group members. We therefore used a 
sandwich covariance estimate to account for intra-cluster dependence132 due to the 
same patient sometimes being included multiple times in Study II and III. In short, the 
sandwich covariance estimator does not assume that the variance is constant and 
therefore provides more valid estimates of the standard error in data with some degree 
of dependence. 
 
Logistic regression (Study IV) 
The logistic regression model is a regression model that can be used when the outcome 
is binary and can take only two values. It predicts the odds of acquiring the outcome 
based on the values of different exposures.133 The odds can be defined as the probability 
that an individual with a specific exposure acquires the outcome of interest divided with 
the probability that the same individual does not. The association between the studied 
exposure and outcome is measured as an odds ratio. As in Cox proportional hazard 
regression, several exposures/covariates can be taken into account, allowing adjustment 
for confounding factors. We used logistic regression to study odds ratios for 
benzodiazepine initiation and long-term use in Study IV, as we were interested in if rather 
than when the patients initiated benzodiazepine treatment or became long-term users. 
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4 RESULTS 
 
4.1 Study I 
Sixty-two percent of the included patients with a first-time bipolar disorder diagnosis 
were female and the mean age at diagnosis was 40 years (SD 14.5). In total, 72% of 
patients filled a prescription of a mood-stabilizer or antipsychotic within three months 
after diagnosis, and after one year, 79% of all patients had filled at least one prescription 
of a prophylactic drug. Rates of prescription fills were somewhat higher among patients 
diagnosed in inpatient care compared to outpatient care. 
 
Table 3 shows potential predictors and their association with treatment initiation within 
three months after diagnosis. For patients diagnosed in inpatient care, the strongest 
predictors for treatment initiation were the length of the index hospitalization (aHR 2.18, 
95% CI 2.022.35, for hospitalizations of ≥28 days, compared to 7 days), previous use 
of mood-stabilizers or antipsychotics (aHR 1.24, 95% CI 1.171.31), and a mixed episode 
at the time of diagnosis (aHR 1.23, 95% CI 1.091.38). Comorbid personality disorder 
and alcohol/substance abuse were negatively associated with treatment initiation. 
 
For patients diagnosed in outpatient care, the strongest predictors for treatment 
initiation were previous use of mood-stabilizers or antipsychotics (aHR 1.78, 95% CI 
1.73-1.84) and a mixed episode at the time of diagnosis (aHR 1.32, 95% CI 1.231.41), 
whereas a manic episode at the time of diagnosis significantly reduced the probability of 
treatment initiation. 
 
 
 
 
 
N % (95% CI) N % (95% CI)
Gender
Male 2 805 75.9 Ref=1 9 191 74.3 Ref = 1
Female 4 063 79.1 1.03 (0.97-1.09) 15 711 75.0 1.02 (0.99-1.05)
Age at BD diagnosis (years)
<25 1138 80.4 Ref=1 4 506 74.1 Ref=1
25-59 4 512 78.0 1.00 (0.92-1.08) 17 922 75.1 0.97 (0.93-1.01)
≥60 1 218 74.5 0.90 (0.84-0.96) 2 474 73.1 0.95 (0.91-0.98)
Previous psychiatric care, past five years 4 591 78.5 1.02 (0.96-1.09) 17 456 75.5 1.04 (1.00-1.07)
Affective state at BD diagnosis
Depressed 1 258 83.7 1.13 (1.05-1.22) 4 079 77.0 1.09 (1.05-1.13)
Manic 1 748 76.9 1.01 (0.93-1.09) 1 449 44.2 0.51 (0.47-0.56)
Hypomanic 549 71.9 1.02 (0.91-1.13) 1 575 66.0 0.93 (0.87-0.99)
Mixed 387 85.5 1.23 (1.09-1.38) 1107 82.4 1.32 (1.23-1.41)
Unspecified 2 926 75.8 Ref=1 16 692 77.2 Ref=1
Presence of psychotic symptoms at BD diagnosis 1145 80.7 1.01 (0.93-1.10) 726 55.0 0.96 (0.86-1.07)
Duration of index hospitalization (days)
<7 2 167 63.6 Ref=1
27-jul 2 755 81.9 1.86 (1.73-1.99)
≥28 1 946 87.8 2.18 (2.02-2.35)
Comorbid personality disorder 753 74.1 0.87 (0.79-0.96) 2 305 75.3 0.99 (0.94-1.04)
Comorbid substance/alcohol use disorder 1 361 71.5 0.86 (0.80-0.93) 3 568 73.0 1.00 (0.96-1.05)
Patients
Initiated 
prophylactic 
treatment
Adjusted hazard 
ratio
Table 3. Predictors for initiation of prophylactic treatment within three months after a first time bipolar disorder diagnosis
Diagnosed in inpatient care (N=6 868) Diagnosed in outpatient care (N=24 902)
Filled prescriptions of any mood stabilizing drug 
the year before BD diagnosis
2 995 83.9 1.24 (1.17-1.31) 11 242 88.2 1.78 (1.73-1.84)
Patients
Initiated 
prophylactic 
treatment
Adjusted hazard 
ratio
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4.2 Study II 
Pharmacological relapse prevention with lithium, valproate, olanzapine, quetiapine or 
aripiprazole was used after 78% of the included index hospitalizations for mania. 
Monotherapies and combination therapies were equally common. The overall 
rehospitalization risk for patients who started relapse prevention was 39%, compared to 
46% for patients who did not fill any prescriptions of prophylactic drugs during the first 
four weeks after discharge. 
 
Patients on combination therapy with two drugs had a significantly lower 
rehospitalization risk compared to untreated patients (aHR 0.76, 95% CI 0.77-0.94). 
Similar non-significant trends were seen for monotherapies and combination therapies 
of three or more drugs. One year rehospitalization risks ranged from 32% to 65% across 
treatment groups (Table 4). In the monotherapy group, no drug was associated with a 
significantly altered risk of rehospitalization compared with lithium (Table 4). 
Combination therapy with olanzapine and valproate or olanzapine and lithium were 
associated with the lowest rehospitalization risks of all treatment options (aHRs 0.76, 
95% CI 0.62-0.93, and 0.83, 95% CI 0.70-0.98, respectively) (Table 4 and Figure 5). 
 
 
 
N N % Unadjusted Adjusted
Monotherapies
Lithium 859 362 42.1 Ref=1 Ref=1
Valproate 404 155 38.4 0.86 (0.71-1.04) 0.89 (0.74-1.07)
Olanzapine 775 278 35.9 0.81 (0.69-0.95) 0.90 (0.77-1.06)
Quetiapine 344 139 40.4 0.93 (0.77-1.13) 0.91 (0.75-1.11)
Aripiprazole 114 55 48.2 1.26 (0.95-1.68) 1.13 (0.85-1.51)
Combination therapies
Lithium + Valproate 202 92 45.5 1.06 (0.84-1.33) 0.96 (0.76-1.21)
Lithium + Olanzapine 729 246 33.7 0.74 (0.63-0.87) 0.83 (0.70-0.98)
Lithium + Quetiapine 316 137 43.4 0.99 (0.82-1.21) 0.95 (0.78-1.15)
Lithium + Aripiprazole 98 43 43.9 1.08 (0.79-1.48) 0.87 (0.63-1.20)
Valproate + Olanzapine 402 130 32.3 0.69 (0.57-0.84) 0.76 (0.62-0.93)
Valproate + Quetiapine 167 70 41.9 1.00 (0.77-1.29) 0.87 (0.68-1.13)
Valproate + Aripiprazole 51 19 37.3 0.92 (0.58-1.45) 1.01 (0.64-1.61)
Olanzapine + Quetiapine 68 27 39.7 0.92 (0.62-1.36) 0.86 (0.58-1.28)
Olanzapine + Aripiprazole 44 15 34.1 0.82 (0.49-1.38) 0.84 (0.50-1.40)
Quetiapine + Aripiprazole 17 11 64.7 1.74 (0.95-3.16) 1.42 (0.78-2.59)
Lithium + Valproate + Olanzapine 157 62 39.5 0.87 (0.67-1.14) 0.89 (0.68-1.17)
Lithium + Valproate + Quetiapine 84 34 40.5 0.95 (0.67-1.34) 0.86 (0.61-1.23)
Lithium + Olanzapine + Quetiapine 53 20 37.7 0.91 (0.58-1.42) 0.81 (0.51-1.27)
Other combinations of ≥3 drugs 172 73 42.4 1.06 (0.83-1.36) 0.97 (0.75-1.25)
No prescription fills 1 446 658 45.5 1.12 (0.99-1.27) 1.03 (0.90-1.17)
Table 4. Risks of psychiatric rehospitalization in relation to prescription fills after
 hospital discharge
Total Rehospitalizations
Rehospitalization, 
Hazard Ratio (95% CI)
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Figure 5. Adjusted hazard ratios of rehospitalization by prescription fills after hospital 
discharge (lithium monotherapy used as reference with aHR 1.0). 
 
 
4.3 Study III 
Treatment failure within one year after a manic episode was seen in 85% of patients  
(4 871 cases). Of these, 2 667 patients switched treatment, 1 108 discontinued treatment 
and 1 096 were rehospitalized during ongoing treatment.  
 
Whereas a slight majority (58%) of patients used monotherapy, the risk of treatment 
failure was significantly lower for patients on combination therapy (Figure 6 and Table 
5). Combination treatment with lithium + valproate + quetiapine or lithium + valproate + 
olanzapine was associated with the lowest overall risks of treatment failure, with aHRs 
of 0.40 (95% CI 0.300.54) and 0.55 (95% CI 0.450.68), respectively, compared to 
lithium monotherapy. The same combination treatments were associated with the lowest 
rates of medication switch and discontinuation of all treatment options. Further, lithium 
+ valproate + quetiapine was the only treatment alternative associated with a 
significantly lower rehospitalization risk than lithium monotherapy (aHR 0.57, 95% CI 
0.320.99). 
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Comparing monotherapies only, all atypical antipsychotics were associated with a 
significantly higher risk of treatment failure compared to single use of lithium, whereas 
monotherapy with valproate was associated with a non-significantly higher risk 
compared to lithium (Figure 6).  
 
 
Figure 6. Adjusted hazard ratios of all cause treatment failure by type of active treatment 
(lithium monotherapy used as reference with aHR 1.0). 
 
 
 
N % Adjusted HR % Adjusted HR % Adjusted HR % Adjusted HR
(95% CI) (95% CI) (95% CI) (95% CI)
Monotherapies
Lithium 1 133 87.0 Ref=1 46.5 Ref=1 20.2 Ref=1 20.4 Ref=1
Valproate 525 87.4 1.10 (0.981.23) 44.2 1.06 (0.911.24) 26.1 1.38 (1.111.71) 17.1 0.94 (0.741.21)
Olanzapine 1 013 93.3 1.51 (1.371.66) 53.5 1.59 (1.401.80) 26.1 1.73 (1.432.09) 13.7 1.06 (0.851.32)
Quetiapine 468 90.2 1.20 (1.061.34) 56.0 1.34 (1.151.56) 16.5 0.99 (0.761.29) 17.7 1.02 (0.791.32)
Aripiprazole 146 92.5 1.28 (1.071.54) 60.3 1.48 (1.171.86) 15.8 1.09 (0.711.69) 16.4 0.95 (0.621.45)
Combination therapies
Lithium + Valproate 217 83.4 0.72 (0.620.85) 38.2 0.62 (0.490.79) 17.5 0.63 (0.440.89) 27.6 1.05 (0.781.40)
Lithium + Olanzapine 696 76.5 0.69 (0.620.76) 41.8 0.72 (0.630.84) 16.9 0.50 (0.400.62) 17.9 0.84 (0.671.04)
Lithium + Quetiapine 314 79.6 0.66 (0.570.76) 40.4 0.61 (0.500.74) 12.7 0.43 (0.300.60) 26.4 1.08 (0.841.39)
Lithium + Aripiprazole 92 79.3 0.66 (0.520.84) 45.7 0.74 (0.541.01) 13.0 0.46 (0.260.83) 20.7 0.70 (0.441.13)
Valproate + Olanzapine 415 83.6 0.82 (0.720.93) 45.5 0.86 (0.731.02) 21.0 0.67 (0.520.86) 17.1 0.85 (0.651.11)
Valproate + Quetiapine 171 76.6 0.61 (0.510.74) 38.6 0.59 (0.450.76) 14.0 0.45 (0.300.69) 24.0 0.86 (0.611.20)
Valproate + Aripiprazole 50 86.0 0.93 (0.691.27) 40.0 0.78 (0.501.23) 22.0 0.94 (0.511.72) 24.0 1.13 (0.632.03)
Olanzapine + Quetiapine 62 91.9 1.20 (0.911.57) 64.5 1.33 (0.961.84) 8.1 0.66 (0.271.61) 19.4 1.13 (0.632.04)
Lithium + Valproate + Olanzapine 136 76.5 0.55 (0.450.68) 32.4 0.46 (0.340.63) 15.4 0.39 (0.250.61) 28.7 0.99 (0.701.39)
Lithium + Valproate + Quetiapine 68 64.7 0.40 (0.300.54) 38.2 0.45 (0.300.66) 7.4 0.18 (0.070.44) 19.1 0.57 (0.320.99)
Other combinations 207 75.8 0.62 (0.520.73) 42.0 0.64 (0.510.81) 7.7 0.26 (0.160.44) 26.1 0.99 (0.731.33)
Table 5. Comparative risks for treatment failure with each monotherapy and combination, presented as absolute risks and
hazard ratios with 95% confidence intervals
All cause 
treatment failure
Medication                   
switch
Medication 
discontinuation
Psychiatric 
rehospitalization
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4.4 Study IV 
Out of the 21 883 included patients, 6 307 (29%) filled at least one prescription of a 
benzodiazepine or Z-drug within one year. The median duration of benzodiazepine/Z-
drug use was 30 days (interquartile range: 14100). In total, 1 376 patients (22% of all 
initiators) became long-term users. 
 
The likelihood of benzodiazepine/Z-drug initiation decreased steadily with age, with an 
aOR of 0.64 (95% CI 0.56-0.73) for patients ≥60 years, compared to patients 30 years. 
Women were more likely to initiate treatment, as were individuals with a high 
education or income level. Further, a first time bipolar disorder diagnosis strongly 
predicted benzodiazepine/Z-drug initiation (aOR 1.87, 95% CI 1.74-2.02), as did a 
recent psychiatric hospitalization (aOR 2.27, 95% CI 2.08-2.47). Other predictors for 
benzodiazepine initiation included a recent diagnosis of mania or depression, comorbid 
anxiety disorder/OCD, concomitant use of antipsychotics without mood-stabilizing 
indication, and concomitant use of four or more psychotropic drugs.  
 
Contrary to what was seen for initiation, high age strongly predicted long-term use, 
with sixty plus year olds having almost twice the odds of becoming long-term users 
compared to patients 30 years. Low income and being divorced or widowed also 
predicted long-term use. Indicators for bipolar disorder disease activity and current 
affective morbidity were not associated with long-term use, although concurrent use of 
antidepressants or lamotrigine was (aORs 1.24, 95% CI 1.07-1.42, and 1.21, 95% CI 
1.041.42). Other factors associated with increased odds of long-term use included a 
first-time bipolar disorder diagnosis, history of suicidality or self-harm, comorbid non-
borderline personality disorder, and concurrent use of psychostimulants (aOR 1.78, 
95% CI 1.33-2.39), non-mood-stabilizing antipsychotics (1.53, 95% CI 1.29-1.82), or ≥4 
psychotropic drugs (aOR 1.47, 95% CI 1.20-1.82). 
 
Prescription related factors and their association with long-term use are displayed in 
Table 6. Among those who filled a prescription of alprazolam or clonazepam, the aOR 
for long-term use was 2.03 (95% CI 1.30-3.18), and 3.78, (95% CI 2.24-6.38), 
respectively, compared to diazepam users. Patients who were initiated on ≥2 
benzodiazepines and/or Z-drugs also had significantly increased risk of becoming long-
term users (aOR 2.46, 95% CI 1.79-3.38). 
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N % % OR (95% CI) aOR (95% CI)
Substance
Diazepam 422 81.5 18.5 Ref=1 Ref=1
Oxazepam 1 043 80.3 19.8 1.09 (0.811.45) 1.09 (0.811.46)
Lorazepam 27 81.5 18.5 - -
Alprazolam 142 68.3 31.7 2.05 (1.333.15) 2.03 (1.303.18)
Clonazepam 80 53.8 46.3 3.80 (2.296.28) 3.78 (2.246.38)
Nitrazepam 170 75.9 24.1 1.40 (0.912.15) 1.46 (0.932.27)
Flunitrazepam 34 88.2 11.8 - -
Triazolam 5 100.0 0.0 - -
Zopiclone 2 750 79.4 20.7 1.15 (0.881.49) 1.19 (0.911.56)
Zolpidem 1 041 81.6 18.4 1.00 (0.751.34) 1.12 (0.831.51)
Zaleplon 53 88.7 11.3 - -
≥2 substances 540 64.1 35.9 2.47 (1.833.35) 2.46 (1.793.38)
Size of prescription
≤28 tablets 2 584 84.0 16.0 Ref=1 Ref=1
>28 tablets 3 723 74.1 25.9 1.83 (1.612.09) -
Prescriber
General Practitioner 99 83.8 16.2 Ref=1 Ref=1
Psychiatrist 1 571 74.6 25.4 1.43 (1.091.87) 1.36 (1.021.81)
Other 158 67.7 32.3 1.51 (1.072.13) 1.29 (0.891.86)
Table 6. Prescription related factors and their association with long-term use
Total 
number of 
patients
Crude OR for long-
term use
Adjusted OR for 
long-term use
Subsequent 
short-term 
users
Subsequent 
long-term 
users
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5 METHODOLOGICAL CONSIDERATIONS 
 
5.1 Potential sources of error in the presented studies 
The reliability of study results depends on what errors may have afflicted the study 
design and data. Studies can contain two general types of error: systematic error (bias) 
and random error.68 Bias is defined as any trend in the collection, analysis, interpretation, 
publication or review of data that can lead to conclusions systematically different from 
the truth.134 It can be classified into three main categories: selection bias, information bias 
and confounding.  
 
Selection bias 
Selection bias refers to a situation where there is a difference in the association between 
exposure and outcome between individuals who participate in the study versus those 
who do not.68 The study populations in this thesis were selected based on data from the 
NPR and/or PDR, two national population-based registers with an estimated 99% 
coverage of the Swedish population. This basis for selection strongly limits the risk for 
selection bias, since virtually all eligible patients in Sweden were included and loss to 
follow-up was minimal.  
 
Information bias 
Information bias arises when information on the studied exposures and/or outcomes is 
incorrect.68 The use of prospectively collected register data prevents misclassification of 
exposures based on outcome status. However, register-data have a lower resolution 
compared to, for example, hospital records, resulting in blunter measurements of 
clinical factors. We aimed to reduce the number of patients misclassified as having 
bipolar disorder through excluding patients with a diagnosis of schizophrenia or 
schizoaffective disorder on the same day as their first bipolar disorder diagnosis (Study 
I), patients with a previous diagnosis of schizophrenia, schizoaffective disorder or 
dementia (Study II and IV), or considered these patients non-eligible (Study III). This 
resulted in 1%15% of eligible patients being excluded. 
 
In general, the prevalence of psychiatric comorbidities recorded through recent 
psychiatric diagnoses in the NPR was somewhat lower than expected, indicating 
missing data. For example, the estimated prevalence rates of anxiety disorders ranged 
from 9% to 14% in our study populations, whereas the lifetime prevalence of anxiety 
disorders in bipolar disorder may be as high as 50%,22 with an estimated point 
prevalence of generalized anxiety disorder alone of 12%.96 Any missing data on 
comorbidities is likely to be non-differential, and would therefore have diluted the 
observed associations. The dilution of associations between comorbodities and study 
outcomes, and the missing data itself, may have resulted in some degree of residual 
confounding (discussed below). 
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Prescription fills were used as a proxy for initiated or ongoing treatment in all four 
studies. This may be an imperfect measure, as we do not know to what degree patients 
use their dispensed drugs. Further, combination treatments were defined based on fills 
of two or more prophylactic drugs within a period of two (Study III) or four (Study II) 
weeks, which could have resulted in some degree of misclassification, as it is impossible 
to distinguish the addition of one drug to another from a prompt change of monotherapy 
through register data. These misclassifications are also likely to be non-differential, and 
would therefore have diluted the observed drug effects, especially the effects of 
combination treatments. Lastly, the lack of data on drug prescriptions that were never 
filled limited the strictness of the intention-to-treat design used in Study II, and prevented 
us from reaching firm conclusions on adherence to prescribed medication. 
 
Confounding 
A confounder is a variable that influences both the exposure and the outcome and may 
distort the observed association between exposure and outcome through increasing or 
decreasing its strength.68 For example, high age was found to be an important risk factor 
for psychiatric rehospitalization in Study II. As patients who have lived longer are more 
likely to have a history of self-harm, we therefore had to consider and adjust for the 
impact of age when studying the association between self-harm and rehospitalization.  
 
In pharmacoepidemiological studies, confounding by indication is one of the most 
important limitations to consider. Confounding by indication arises from the fact that 
patients who take one drug usually differ from those who take another drug, with regard 
to disease severity or other factors that may impact the outcome.68 We handled potential 
confounding by indication through: 1) investigating the association between potential 
confounders (clinical and sociodemographic characteristics) and the outcome of interest, 
2) stratification (Study I), and 3) adjusting for the effects of confounders through 
multivariable regression models (Study IIV). Several different clinical parameters 
available in register data were used as proxies for illness severity in Study II and III, 
including the length of the index hospitalization, a discharge- or secondary diagnosis 
indicating psychotic symptoms, the number of previous psychiatric admissions and 
psychiatric comorbidities. As already mentioned, missing data due to underreporting of 
psychiatric comorbidities and a lack of indicators of more subtle differences in illness 
severity between patients have likely resulted in some degree of residual confounding. 
 
An alternative strategy for adjusting for confounding would have been to use so called 
propensity score matching. Propensity scores can be seen as a data reduction method, 
through which many covariates are reduced into a single score that can be used to adjust 
for the effects of these. The benefits of propensity score matching are that it saves degrees 
of freedom and therefore does not require the same sample size as multivariable 
regression, and that it can be used to adjust for numerous confounders.135 Because our 
studies were generally well powered, we chose to use multivariable regression, as this 
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allowed us to investigate each specific confounder with regard to its association with the 
study outcome as well as other confounders. We believe this approach is more 
informative and, most importantly, deepens the understanding of the impact of clinical 
and sociodemographic characteristics on treatment choices. 
 
5.2 Random error  
Random errors are chance findings caused by uncontrolled variation between a 
measured value and “the truth”. If the number of observations is sufficiently large, 
random errors cancel each other out, and their sum approaches zero. Random error can 
therefore be limited through increasing the study population.68 The likelihood of an 
observed association to be subject to random error can be estimated statistically through 
confidence intervals. In this thesis, we used a significance level of 0.05, meaning that if 
each study was to be repeated 100 times, the confidence interval would be expected to 
include the true value in 95 of those studies, respectively. The large number of included 
patients in our studies limited the risk for random error. As the risk for random error 
increases with the number of performed statistical tests, we thoroughly selected the 
potential confounding factors included in our analyses. Even so, random errors due to 
multiple testing cannot be ruled out.  
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6 INTERPRETATIONS AND CONCLUSIONS 
 
At the time of our first study, it was largely unknown to what extent newly diagnosed 
bipolar disorder patients used prophylactic treatment. We found that slightly less than 
three out of four patients started prophylactic treatment within three months of 
diagnosis, and that one in five patients still did not have access to relapse prevention after 
one year. Considering that the mean age at diagnosis was almost 40 years and that a 
majority of patients had been in contact with psychiatric care in the past years, these 
numbers suggest a considerable treatment delay, as reported by others.13,25,73 Such 
treatment delay is problematic as the effectiveness of prophylactic drugs seem to be 
higher in the early phase of bipolar illness,75,76 and may impair the prognosis.15,74 
 
Interestingly, the length of the index hospitalization was the strongest predictor for 
initiation of prophylactic treatment among inpatients. A long hospitalization likely 
reflects a more severe affective episode, which may increase the incentive for subsequent 
prophylactic treatment. Further, a short hospitalization may be a result of a weaker 
therapeutic alliance. It may however also be the case that long hospitalizations per se are 
conducive to treatment adherence through allowing complete remission and facilitating 
individually tailored pharmacotherapy. Not surprisingly, previous use of mood-
stabilizers or antipsychotics strongly predicted continuous use of prophylactic treatment 
after diagnosis, whereas patients who were diagnosed with mania in outpatient care had 
the lowest treatment initiation rate, likely reflecting the difficulty of managing manic 
patients in outpatient care. 
 
In the second study, we found that the rehospitalization risk after a manic episode 
remains high, despite a wide use of modern treatment alternatives. Contrary to our 
hypothesis and to previous observational findings,57-59,64,65,136 we did not observe a 
superior effectiveness of lithium monotherapy. Instead, patients initiated on 
combination therapy with two prophylactic drugs was the only group with a 
significantly lower rehospitalization risk compared to untreated patients. A 
combination of olanzapine and valproate or lithium appeared to be most successful 
with regard to reducing the rehospitalization risk. Other combinations such as 
olanzapine and aripiprazole also appeared favorable, although the estimated hazard 
ratios were non-significant due to small numbers of patients.  
 
Similarly, in Study III we found that combination therapies were associated with a 
significantly lower risk of overall treatment failure compared with monotherapies. 
Patients combining lithium, valproate, and quetiapine had a 60% lower risk of 
treatment failure compared to patients on lithium monotherapy, with lower rates of 
medication switch, discontinuation, and rehospitalization compared with patients on 
any other regimen. Although lithium monotherapy did not appear to significantly 
reduce the rehospitalization risk compared to other monotherapies in Study II, 
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continuous monotherapy with lithium or valproate did appear more favorable with 
regard to treatment failure than single use of olanzapine, quetiapine, or aripiprazole in 
Study III, supporting previous observational findings.57-59  
 
Despite the majority of treatment guidelines recommending monotherapy as first-line 
treatment,46,52,54,79 43% of patients used two or more anti-manic drugs after hospital 
discharge. We observed lower rates of discontinuation and medication switch among 
patients on combination therapy, somewhat contrary to previous findings indicating a 
lower tolerability of combination treatments vs. monotherapies.137 Possibly, this 
reflects a higher tolerability of combination treatment after a manic episode, or that the 
perceived benefits of combination treatments with regard to symptomatic and 
syndromic remission are high enough to outweigh any negative effects. 
 
The more successful outcomes associated with combination therapy after a manic 
episode observed in Study II and III provide real-world evidence in support of existing 
RCT-findings.138-142 Notably, previously performed observational comparative-
effectiveness studies have either not included any combination therapy,58,64,65 lumped 
all combination therapies together in one group,55,57,143 or studied a very limited 
number of combination treatments.56 The majority have further included a mix of 
patients with bipolar disorder type I and II,57-59,64,65 which may limit possible 
comparisons with our data and most RCTs.   
 
In the fourth and final study, we found that more than one in five patients with bipolar 
disorder who initiated benzodiazepine/Z-drug treatment continued such treatment for 
six months or more, despite recommendations stating that these drugs should be used 
for a maximum of four weeks. The highest risk of long-term use was observed in 
patients who used clonazepam or alprazolam, both of which belong to the most 
common drugs of abuse worldwide.144-146 Clonazepam and alprazolam are known to 
cause a more severe physical dependence than other benzodiazepines,147-149 which may 
explain the higher rates of long-term use. In addition, both substances are used in the 
acute management of panic attacks, which sometimes require a long treatment 
duration. The higher rate of long-term use among patients on benzodiazepine/Z-drug 
polytherapy supports previous findings, 118 and may be explained by combinations of 
different substances likely boosting dependence. 
 
The strong correlation between high age and long-term benzodiazepine/Z-drug use 
found in our study and seen in several previous studies117-120,150 is concerning, given 
that physiological age-related changes make patients more vulnerable to harmful side 
effects.107,151 Conversely, the youngest age group had the highest benzodiazepine/Z-
drug initiation rate, possibly prompted by higher levels of mixed symptoms, agitation 
and suicidal thoughts.152,153 Notably, acute affective morbidity predicted 
benzodiazepine initiation but was unrelated to long-term use. The finding that 
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concurrent use of psychostimulants strongly predicted long-term use will warrant 
further study. In conclusion, a circa 20% risk for long-term use was observed across all 
benzodiazepines and Z-drugs, suggesting that a certain level of vigilance is needed 
whenever patients initiate benzodiazepine/Z-drug treatment.  
 
 
Conclusions: 
 A substantial proportion of newly diagnosed bipolar disorder patients do not 
use prophylactic treatment. 
 
 Efforts to reduce treatment delay should especially target patients who are naïve 
to mood-stabilizers and antipsychotics or diagnosed with bipolar disorder 
during a brief hospitalization. 
 
 Longer psychiatric hospitalizations may per se be conducive to increased use of 
prophylactic treatment after diagnosis. 
 
 The one-year rehospitalization risk after a manic episode is considerable also 
for patients who initiate prophylactic treatment.  
 
 Combination therapies including olanzapine and a classic mood-stabilizer seem 
beneficial for reducing the rehospitalization risk after a manic episode. 
 
 Our results suggest that polytherapy is more effective, in terms of lower rates 
of treatment failure, than monotherapy after a manic episode. 
 
 Likewise, lithium monotherapy seems to be more effective than monotherapy 
with olanzapine, quetiapine or aripiprazole with regard to treatment failure. 
 
 Benzodiazepines and Z-drugs are widely used during acute affective episodes, 
but affective morbidity is largely unrelated to long-term benzodiazepine use.  
 
 Patients who use clonazepam or alprazolam are at high risk for long-term use, 
and these substances should therefore be used restrictively when treating 
anxiety or insomnia in bipolar disorder.  
 
 Polytherapy with benzodiazepines and/or Z-drugs should be avoided. 
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7 FUTURE PERSPECTIVES 
 
Several questions and ideas for future studies have emerged during the course of this 
doctoral project: 
 
 Is there a certain time point when combination therapies stop being beneficial 
after a manic episode? 
 
 Do suicide risks differ between patients on different maintanance treatments? 
 
 Is combination treatment more effective than monotherapy in reducing the 
suicide risk? 
 
 Is the comparative effectiveness of prophylactic drugs and combination 
therapies different in patients with bipolar disorder type II compared to bipolar 
disorder type I? 
 
 Why does combination treatment seem more beneficial after a manic episode, 
despite previous data indicating higher levels of side effects? 
 
 Does non-adherence to maintenance treatment predict benzodiazepine use? 
 
 Is the increased risk of long-term benzodiazepine use in patients on concurrent 
treatment with psychostimulants a sign of a generally increased risk for abuse in 
this population? 
 
 Comparative effectiveness studies also need to focus on interepisodic morbidity 
and function in bipolar disorder. One way to capture these aspects in Swedish 
register data is through work absenteeism/presenteeism, sick leave and 
disability pension. 
 
 Is sick-leave associated with the type of maintenance teratment? 
 
 Is disability pension associated with the type of maintenance teratment? 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
 
Bipolär sjukdom drabbar drygt två procent av befolkningen i Sverige och har en liknande 
utbredning globalt. Sjukdomen orsakar ett påtagligt lidande för den drabbade genom att 
medföra återkommande perioder av hyperaktivitet och förhöjd eller irritabel 
grundstämning (så kallade manier eller hypomanier) och depressioner. Patienter med 
bipolär sjukdom har därtill en kraftigt förhöjd självmordsrisk. Litium har sedan 1960-
talet utgjort grundpelaren i behandlingen genom att motverka nya maniska och 
depressiva skov. Under senare år har ett stort antal moderna läkemedel godkänts som 
förebyggande behandling vid bipolär sjukdom och dessa har i snabb takt delvis kommit 
att delvis ersätta litium. I dagsläget finns det knapp kunskap kring vilka av dessa 
behandlingsalternativ och preparatkombinationer som är mest effektiva.  
 
Syftet med detta doktorandprojekt har varit att undersöka användningen av 
förebyggande läkemedelsbehandling hos patienter med nydiagnostiserad bipolär 
sjukdom samt att jämföra effektiviteten mellan olika förebyggande behandlingsalternativ 
för att på sikt underlätta valet av behandling för läkare och patienter. Vi har vidare 
studerat riskfaktorer för att patienter med bipolär sjukdom ska bli långtidsanvändare av 
beroendeframkallande lugnande läkemedel och sömnmedel (bensodiazepiner och Z-
preparat).  
 
I de fyra kohortstudier som ingår i avhandlingen har vi följt upp stora grupper av 
patienter genom att länka data från rikstäckande hälsoregister vid Socialstyrelsen 
(Patientregistret, Läkemedelsregistret och Dödsorsaksregistret). Vi har därtill använt 
socioekonomisk och demografisk information från register vid Statistiska centralbyrån.  
 
Studie I 
Då förebyggande läkemedelsbehandling är som mest effektiv tidigt under 
sjukdomsförloppet är det angeläget att patienter erbjuds sådan behandling så snart som 
möjligt efter diagnos. I den första studien undersökte vi hur stor andel av alla patienter i 
Sverige som inleder behandling inom tre månader efter att ha diagnostiserats med 
bipolär sjukdom. Studien inkluderade 31 770 patienter som följdes under ett års tid. Vi 
fann att 72% av patienterna inledde behandling inom tre månader efter diagnos. 
Patienter som erhållit sin diagnos i samband med ett långt slutenvårdstillfälle (fyra 
veckor eller längre) i psykiatrin inledde förebyggande behandling i störst utsträckning. 
Likaså hade patienter som tidigare behandlats med något stämningsstabiliserande 
preparat (litium, antiepileptikum eller antipsykotikum) en högre sannolikhet att inleda 
eller fortsätta förebyggande behandling efter diagnos.  
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Studie II 
I den andra studien jämförde vi risken för återinläggning mellan patienter som använt 
olika typer av återfallsförebyggande behandling efter ett slutenvårdstillfälle för mani. 
Studien innehöll uppföljningsdata från totalt 6 502 manivårdtillfällen. Patienterna 
klassificerades baserat på vilka läkemedel de hämtade ut under de första fyra veckorna 
efter utskrivning och följdes under ett års tid. Vi fann att återinläggningsrisken var något 
lägre hos patienter som inledde förebyggande behandling inom fyra veckor efter 
utskrivning (39%) jämfört med patienter som inte gjorde det (46%). Patienter som 
använde en kombination av olanzapin och litium eller valproat hade lägst 
återinläggningsrisk av alla, motsvarande 24% respektive 17% lägre risk att återinläggas 
jämfört med patienter som behandlades med litium i monoterapi.  
 
Studie III 
I den tredje studien jämförde vi risken för behandlingsmisslyckande (eng: ”treatment 
failure”) mellan patienter som använde olika typer av återfallsförebyggande behandling 
efter en manisk episod. Behandlingsmisslyckande definierades som byte av behandling, 
behandlingsavbrott eller återinläggning i psykiatrin trots pågående behandling. Studien 
innehöll uppföljningsdata från 5 713 manivårdtillfällen. Vi fann att risken för 
behandlingsmisslyckande var signifikant lägre hos patienter som behandlades med 
kombinationsterapi jämfört med monoterapi. Trippelterapi med litium, valproat och 
quetiapin eller olanzapin hade lägst risk att misslyckas och var associerad med 60% 
respektive 45% lägre misslyckanderisk jämfört med litium i monoterapi. 
 
Studie IV 
I den fjärde och sista studien undersökte vi omfattningen av långtidsanvändning av 
beroendeframkallande lugnande medel och sömnmedel bland patienter med bipolär 
sjukdom samt riskfaktorer för långtidsanvändning. Vi inkluderade 21 883 patienter som 
inte behandlats med bensodiazepiner eller Z-preparat under det senaste året och följde 
dessa under ett års tid. Patienter som hämtade ut bensodiazepiner eller Z-preparat under 
uppföljningstiden följdes i ytterligare ett år från behandlingsstart. Totalt inledde 6 307 
patienter (29%) behandling med bensodiazepiner eller Z-preparat. Utav dessa fortsatte 
en femtedel med behandlingen i över 6 månader, trots att behandlings-
rekommendationer förordar en maximal behandlingstid om fyra veckor. Patienter som 
använde preparaten klonazepam eller alprazolam hade fyra respektive två gånger högre 
risk att bli långtidsanvändare jämfört med patienter som använde diazepam. Därutöver 
var polyterapi med två eller flera bensodiazepiner/Z-preparat en viktig riskfaktor för 
långtidsanvändning. 
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